Muin J. Khoury, MD, PhD (Think Tank faculty). Michael F. Iademarco, MD, MPH, William T. Riley, PhD, “Precision Public Health for the Era of Precision Medicine.” Am J Prev Med 2016;50(3):398-401.
“Could the same technologies that propel precision medicine usher in a parallel era of “precision public health” beyond treatment of sick individuals? If precision medicine is about providing the right treatment to the right patient at the right time, precision public health can be simply viewed as providing the right intervention to the right population at the right time.”
Muin J. Khoury and Sandro Galea. “Precision Medicine and Population Health: Dealing With the Elephant in the Room.” Posted August, 2017.
“We suggest that the debate can be resolved by shifting the focus from the health of individuals versus the health of populations to strengthening medicine and public health partnerships that address health problems and disparities and capitalize on emerging data and new technologies, without neglecting well-recognized foundational drivers that are root causes of population health.”
For JAMA subscribers: Muin J. Khoury, MD, PhD; Sandro Galea, MD, DrPH, “Will Precision Medicine Improve Population Health?” JAMA. 2016; 316(13):1357-1358.
Ron Zimmern, “A commentary on Khoury & Galea Will Precision Medicine Improve Population Health.” Aug. 2016.
Are precision medicine and population health disparate disciplines? “Dr. Muin Khoury, who is the director, the founding director, of the Office of Public Health Genomics at the CDC argues that the same technologies that propel personalized medicine such as genetics and big data could usher in a parallel era of what he calls precision public health.”
Ying-Chen Claire Hou, Hung-Chun Yu, Rick Martin, Elizabeth T. Cirulli, et. al. (M. Doney) “Precision medicine integrating whole-genome sequencing, comprehensive metabolomics, and advanced imaging.” National Academy of Science. Dec. 2019.
Paul Terry, PhD, (HERO Senior Fellow). “Introducing “Precision Health Promotion:” The Convergence of Genomics, Health Education, and Lived Experience.” Editorial, The American Journal of Health Promotion, First Published January 29, 2020.
Lyles, C.R., Lunn, M.R., Obedin-Maliver, J. et al. “The new era of precision population health: insights for the All of Us Research Program and beyond.” J Transl Med 16, 211 (2018).
“A limited number of underrepresented research participants can lead to inaccurate scientific conclusions, and increasing their numbers remains challenging in both clinical and genomics research [3]. …. The vision for community engagement in precision population health includes engaging participants in setting research priorities and ensuring that they receive research findings in ways that are accessible, meaningful, and foster education and implementation (in the spirit of community-based participatory research).”
Reenita Das. “Drug Industry Bets Big On Precision Medicine: Five Trends Shaping Care Delivery.” Forbes. Mar 8, 2017, The Death of One Size fits all.
“Precision medicine involving multi-level patient stratification holds the promise of optimizing the cost, time and success rate of pharma clinical trials by co-developing drug medical prescription (Rx) and diagnostics (Dx) for future targeted therapies. … Today, the drug development industry is betting heavily on precision medicine. Leading pharma/biopharma companies have nearly doubled their investment in personalized medicines in the last five years, and expect an additional 1/3 increase over the next five years.”
Ramya Ramaswami, Ronald Bayer, and Sandro Galea, “Precision Medicine from a Public Health Perspective,” Annual Review of Public Health, Vol. 39:153-168 (Volume publication date April 2018).
“More precise stratification of disease also introduces more financial burden and the potential for inefficiencies with little or no tangible clinical benefit. The challenge to population health is that using a disease process to improve individuals’ treatment may have limited utility for the improvement of overall population health. Creating several molecular classifications of one disease entity may subsequently fragment the management of these conditions, which may in turn impose significant strains on existing health services that deliver health care on the basis of organ systems rather than molecular subtypes.”
Michael F. Murray, et. al, “A Proposed Approach for Implementing Genomics-Based Screening Programs for Healthy Adults.” National Academy of Science. Dec. 2018.
David A. Ahlquist, “Universal cancer screening: revolutionary, rational, and realizable.” Precision Oncology, V2: Oct. 2018.
